Lupin Limited , a global pharmaceutical leader, has made significant strides in expanding its product offerings and manufacturing capabilities. The company recently announced two major developments that are set to strengthen its position in the pharmaceutical industry.

PrecisionSphere™ Long-Acting Injectable Platform

Lupin has launched a partnership program to expand its PrecisionSphere™ Long-Acting Injectable Platform. This initiative aims to create collaborations that will extend product lifecycles. In a notable achievement, the first product under this platform has received approval from the U.S. Food and Drug Administration (FDA).

New Manufacturing Facility in Florida

Lupin unveiled plans for a new state-of-the-art pharmaceutical manufacturing plant in Coral Springs, Florida. This expansion is part of the company's strategy to enhance its U.S.-based pharmaceutical capacity, particularly in the production of critical respiratory medicines.

Key details of the Florida facility:

The new facility will focus on producing lifesaving medications such as albuterol inhalers for children with asthma and service members. This move is expected to strengthen Lupin's position as a global respiratory leader and contribute to medicine security in the United States.

Christoph Funke, Chief Technical Operations Officer at Lupin, emphasized that this expansion is a core part of the company's growth strategy and demonstrates its commitment to innovation, quality, and supply chain reliability.

The project has garnered support from Florida's leadership, with Florida Secretary of Commerce J. Alex Kelly highlighting the state's strong foundation for growth in the life sciences and advanced manufacturing sectors.

These developments underscore Lupin's commitment to expanding its product portfolio and manufacturing capabilities, potentially positioning the company for growth in the global pharmaceutical market.

Lupin , a global pharmaceutical leader, has announced plans to establish a state-of-the-art manufacturing facility in Coral Springs, Florida. This significant investment underscores the company's commitment to strengthening its presence in the United States and bolstering its position in the respiratory medicine market.

Investment Details and Economic Impact

Lupin's ambitious project involves a substantial financial commitment and promises to create numerous job opportunities:

The investment will cover research & development, infrastructure, and capital expenditures, significantly boosting the local economy in Broward County.

Focus on Respiratory Medicines

The new facility will primarily focus on the production of respiratory medicines:

• Capacity to manufacture over 25 critical respiratory drugs
• Production of lifesaving albuterol inhalers for children with asthma and service members
• Aim to enhance medicine security and strengthen Lupin's global leadership in respiratory treatments

Strategic Importance

Christoph Funke, Chief Technical Operations Officer at Lupin, emphasized the strategic importance of this expansion, stating, "This new state-of-the-art facility will build on our existing presence in Florida, which is home to Lupin's headquarters and our Advanced Inhalation Research Center."

The project aligns with Florida's economic development goals, as highlighted by Florida Secretary of Commerce J. Alex Kelly: "Lupin's investment will strengthen Florida's position as a leader in life sciences, boost our advanced manufacturing capabilities and enhance the state's medicine security."

Government Support and Partnerships

Lupin's expansion in Coral Springs is backed by significant government support:

• Tax credits and incentives from the state of Florida
• Partnerships with Florida Commerce/Select Florida, City of Coral Springs, Greater Fort Lauderdale Alliance, and Broward County Commission

This collaborative effort aims to diversify the supply chain and ensure affordable, reliable access to critical respiratory therapies, from routine pediatric care to meeting pandemic-scale demand.

About Lupin

Lupin Limited is a global pharmaceutical company with a strong presence in over 100 markets. With its U.S. headquarters in Naples, Florida, Lupin operates 15 manufacturing sites and 7 research centers globally, employing more than 24,000 professionals.

This expansion in Coral Springs represents a significant step in Lupin's growth strategy, reinforcing its commitment to innovation, quality, and supply chain reliability in the pharmaceutical industry.